Ferring in Denmark to launch newly-purchased cancer treatment in Europe

The pharmaceutical company Ferring has purchased rights to a phase-3 cancer treatment, which Ferring's Danish department will be working with in Europe. However, the acquisition does not mean that Ferring will become a cancer-focused firm, says Ferring's CEO in Denmark.

Ferring's department in Ørestad, Copenhagen in Denmark. Photo: Martin Havtorn Petersen/MedWatch

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles